Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma - ScienceDirect
2018 Bone Marrow Failure Highlight - A Novel Therapy for Targeting Acquired Bone Marrow Failure Diseases , Bone Marrow Failure Research Program, Congressionally Directed Medical Research Programs
Frontiers | Innovative Therapeutic and Delivery Approaches Using Nanotechnology to Correct Splicing Defects Underlying Disease | Genetics
Combination of splicing modulator E7107 with BCLxL inhibitors induces... | Download Scientific Diagram
Sensitivity to splicing modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators | Nature Communications
IJMS | Free Full-Text | Therapeutic Targeting of Alternative RNA Splicing in Gastrointestinal Malignancies and Other Cancers | HTML
The synthesis and evaluation of the antiproliferative activity of deacidified GEX1A analogues | The Journal of Antibiotics
Unii-R60dzx1E2N | C40H66N2O9 - PubChem
The catalytic spliceosome inhibitor E7107 induces IR and has potent... | Download Scientific Diagram
Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma - eBioMedicine
RCSB PDB - 5ZYA: SF3b spliceosomal complex bound to E7107
Preclinical Evaluation and Development of New Therapeutic Strategies in Myeloma | Wiita Lab at UCSF
IJMS | Free Full-Text | Therapeutic Targeting of Alternative RNA Splicing in Gastrointestinal Malignancies and Other Cancers | HTML
Roles and mechanisms of alternative splicing in cancer — implications for care | Nature Reviews Clinical Oncology
Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma | bioRxiv
A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors
E7107
A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors
Splicing modulation by E7107 treatment broadly affects the CLL... | Download Scientific Diagram
RCSB PDB - 5ZYA: SF3b spliceosomal complex bound to E7107
Splicing modulation by E7107 treatment broadly affects the CLL... | Download Scientific Diagram
E7107 | CAS#630100-90-2 | spliceosome inhibitor | MedKoo
Scalable Synthesis of 17S-FD-895 Expands the Structural Understanding of Splice Modulatory Activity - ScienceDirect
Dysregulated Alternative Splicing Landscape Identifies Intron Retention as a Hallmark and Spliceosome as a Therapeutic Vulnerability in Aggressive Prostate Cancer | bioRxiv
A Comprehensive Overview of Structure‐Activity Relationships of Small‐Molecule Splicing Modulators Targeting SF3B1 as Anticancer Agents - Zhang - 2020 - ChemMedChem - Wiley Online Library
